Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with solid tumors.
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Submitted by webmaster on April 10, 2016
February 14, 2014 to December 31, 2016
CB-839 (Glutaminase Inhibitor)